How many insider trades does FilingIQ track for ONCY?

FilingIQ tracks 14 Form 4 insider transactions for ONCY (ONCOLYTICS BIOTECH INC), covering filings from Jan 16, 2026 onwards. 2 of those were filed in the last 90 days.

Are ONCY insiders net buyers or net sellers?

Across the full Form 4 history for ONCY, 14 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ONCY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ONCY in?

ONCOLYTICS BIOTECH INC (ONCY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $104.64M.

ONCY insider trading

Healthcare

ONCOLYTICS BIOTECH INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

100% / 0%

Market cap

$104.64M

About ONCOLYTICS BIOTECH INC

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Company website: oncolyticsbiotech.com

ONCY insider activity at a glance

FilingIQ has scored 14 insider transactions for ONCY since Jan 16, 2026. The most recent filing in our index is dated Mar 12, 2026.

Across the full history, 14 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ONCY insider trades is 62.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ONCY trades on FilingIQ Raw filings on SEC EDGAR

Latest ONCY Form 4 filings

Kelly Jared Chief Executive Officer

P Feb 12, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ONCY?: FilingIQ tracks 14 Form 4 insider transactions for ONCY (ONCOLYTICS BIOTECH INC), covering filings from Jan 16, 2026 onwards. 2 of those were filed in the last 90 days.
Are ONCY insiders net buyers or net sellers?: Across the full Form 4 history for ONCY, 14 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ONCY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ONCY in?: ONCOLYTICS BIOTECH INC (ONCY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $104.64M.

Methodology & sources

Every ONCY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.